Jaguar health announces presentation of an investigator-initiated evaluation of crofelemer for a severe congenital diarrheal disorder at 2022 digestive disease week

Microvillus inclusion disease (mvid) is a life-threatening and rare autosomal recessive disease that affects newborns and children resulting in significant morbidity and mortality from severe secretory diarrhea san francisco, ca / accesswire / may 24, 2022 / jaguar health, inc. (nasdaq:jagx) today announced the presentation of an investigator-initiated in vitro study evaluating the efficacy of crofelemer, the company's plant-based prescription drug, as a potential anti-diarrheal to mitigate the consequences of microvillus inclusion disease (mvid), a severe congenital diarrheal disorder (cdd), at digestive disease week ® (ddw 2022), which took place may 21-24, 2022 in san diego, ca. "microvillus inclusion disease (mvid) is a life-threatening and rare autosomal recessive disease that affects newborns and children resulting in significant morbidity and mortality from severe secretory diarrhea," said pravin chaturvedi, phd, jaguar health's chief scientific officer and chair of the company's scientific advisory board.
JAGX Ratings Summary
JAGX Quant Ranking